Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.69%
-1.09%
+1.10%
NVAX
Novavax
$8.10
Strengths
Upgraded on attractively valued
Risk Analysis
Investors losing their confidence
Chart
$8.67 (-6.57%)
$7.28 (+11.26%)
$7.19 (+12.66%)
$9.35 (-13.37%)
NVAX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
NVAX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Investors losing their confidence
Future
Future
NVAX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
NVAX Street view is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
NVAX Earnings
The TTM reflects 12-month period, providing review of NVAX financial performance.
The company financial health has moderately improved over the past year
Financial Score
What is NVAX current stock price?
What are NVAX stock strengths?
What risks are associated with NVAX stock?
When is NVAX next earnings report?
What is NVAX market cap and volume?
What is NVAX's current Stock IQ?
Should I buy NVAX stock right now?
Is NVAX a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVAX?
What does a 'Strong Sell' rating mean for NVAX?
What factors influence NVAX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.69%
-1.09%
+1.10%
NVAX
Novavax
Current Price
$8.10
Stock Insights
Strengths
Upgraded on attractively valued
Risk Analysis
Investors losing their confidence
Chart
$8.67 (-6.57%)
$7.28 (+11.26%)
$7.19 (+12.66%)
$9.35 (-13.37%)
NVAX Analysts Opinion
NVAX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Investors losing their confidence
Future
Future
NVAX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
NVAX Street view is unimpressive and have negative views on the near-term outlook
NVAX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Average key support and resistance price levels.
NVAX Earnings
The TTM data reflects the most recent 12-month period, providing overview of NVAX financial performance.
NVAX Financial Health
The company financial health has moderately improved over the past year
Financial Score
NVAX Latest Analysis
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights. Novavax (NVAX) reached $8.48 at the closing of the latest trading day reflecting a -4.83% change compared to its last close.
Thu Oct 16, 2025
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade. Novavax (NVAX) closed the most recent trading day at $9.08 moving 4.02% from the previous trading session.
Mon Oct 6, 2025
Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant . (RTTNews) - Novavax Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavaxs Matrix-M adjuvant. The companies have amended their CLA to expand Sanofis license to include use of Novavaxs Matrix-M adjuvant i
Tue Sep 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
NVAX Stock trends
NVAX Stock performance
NVAX Stock analysis
NVAX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.